NCT02363595 Genomic Predictors of Papillary Microcarcinoma Disease Progression
| NCT ID | NCT02363595 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Papillary Microcarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 750 participants |
| Start Date | 2014-12-31 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 750 participants in total. It began in 2014-12-31 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is being done to answer the following question: What are the specific clinical and molecular features that will help us predict which small thyroid cancers are likely to grow and be problematic? Therefore, the purpose of this study is to identify specific clinical and molecular characteristics that are predictive of tumor progression in small thyroid cancers.
Eligibility Criteria
Inclusion Criteria: * Biopsy proven papillary thyroid cancer (or suspicious for papillary thyroid cancer) confirmed by MSKCC cytopathologist. * Being followed with active surveillance at MSKCC * Biopsied index nodule less than or equal to 2 cm in maximum dimension * Thyroid and neck US performed and interpreted by a MSKCC radiologist within 6 months prior to study entry. Exclusion Criteria: * Biopsied index nodule greater than 2 cm in any dimension * Age less than 18 yrs old
Contact & Investigator
Robert Tuttle, MD
📞 646-888-2716
Robert Tuttle, MD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT02363595 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Papillary Microcarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02363595 currently recruiting?
Yes, NCT02363595 is actively recruiting participants. Visit ClinicalTrials.gov or contact Memorial Sloan Kettering Cancer Center to inquire about joining.
Where is the NCT02363595 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT02363595 clinical trial?
NCT02363595 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Robert Tuttle, MD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 750 participants.